Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments

Página do item simplificado
dc.contributor.authorAggio, Fabio Bom [UNIFESP]
dc.contributor.authorFarah, Michel Eid
dc.contributor.authorSilva, Wagner Camilo
dc.contributor.authorMelo, Gustavo Barreto
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:41:51Z
dc.date.available2016-01-24T12:41:51Z
dc.date.issued2007-02-01
dc.description.abstractPhotodynamic therapy with verteporfin (PDT) significantly reduces the risk of vision loss in patients with exudative age-related macular degeneration (AMD). Indocyanine green-mediated photothrombosis (IMP) and transpupillary thermotherapy (TTT) may also be beneficial for selective cases of exudative AMD. However, a substantial subset of patients responds poorly to these treatments. Intravitreal bevacizumab (IVB) has been recently used in the treatment of exudative AMD, showing both visual and anatomic improvement in the majority of cases.This interventional retrospective case series reports the effects of IVB in 17 eyes with subfoveal neovascular AMD that had undergone repeated PDT (combined or not with triamcinolone acetonide) or PDT followed by either IMP or TTT with poor results. the main outcome measures were visual acuity and tomographic signs of intra/subretinal fluid, as well as central retinal thickness.Most patients received a single IVB injection. the mean follow-up was 4.47 months. the mean logMAR visual acuity changed from 1.17 +/- 0.40 to 1.06 +/- 0.44 (P=0.17). the mean central retinal thickness decreased from 404.05 +/- 245.26 to 280.23 +/- 143.14 mu m (P=0.032). At the end of the study, lack of tomographic signs of intra/subretinal fluid was noted in four (23.5%) eyes. No ocular or systemic side effects were identified.Short-term results with IVB for the treatment of exudative AMD have been promising. However, the chronic retinal and pigment epithelium changes frequently present in eyes that underwent multiple previous treatments may limit complete visual recovery. To our knowledge, this is the first report on the use of IVB for this particular group of AMD patients.en
dc.description.affiliationAlameda Jau, BR-01420000 São Paulo, SP, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Vis Inst, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Vis Inst, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent215-220
dc.identifierhttp://dx.doi.org/10.1007/s00417-006-0412-5
dc.identifier.citationGraefes Archive for Clinical and Experimental Ophthalmology. New York: Springer, v. 245, n. 2, p. 215-220, 2007.
dc.identifier.doi10.1007/s00417-006-0412-5
dc.identifier.issn0721-832X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29484
dc.identifier.wosWOS:000244295200005
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofGraefes Archive for Clinical and Experimental Ophthalmology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectVEGFen
dc.subjectintravitreal bevacizumaben
dc.subjectage-related macular degenerationen
dc.subjectlaseren
dc.subjectphotodynamic therapyen
dc.titleIntravitreal bevacizumab for exudative age-related macular degeneration after multiple treatmentsen
dc.typeinfo:eu-repo/semantics/article
unifesp.campusEscola Paulista de Medicina (EPM)pt
unifesp.departamentoOftalmologia
Arquivos
Coleções
EPM - Artigos